Lilly Aims to Expand Access to Obesity Treatment Mounjaro in India Amid Large-Scale Overweight Population

Eli Lilly Expands Access to Mounjaro in India Amid Growing Demand for GLP-1 Medicines

Key Highlights:

• Eli Lilly plans to expand access to its obesity and diabetes drug Mounjaro (tirzepatide) in India, driven by accelerating demand for GLP-1 medicines.
• Winslow Tucker, President and General Manager for Lilly India, highlighted the company's priority to scale availability, build awareness, and ensure responsible use of the drug.

Market Trends:

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

• Obesity is a major health concern in India, with nearly 100 million people living with obesity or overweight, which is directly linked to cardiovascular disease and other serious complications.
• The rising use of GLP-1 medicines is a meaningful step forward for chronic disease care, and India could see faster adoption as more companies enter the market following the expected launch of generic semaglutide later this year.

Product Development and Safety:

• Mounjaro, launched in India in March last year, has seen strong uptake, and real-world evidence from India has been consistent with global clinical-trial data.
• Lilly continues to collect and report adverse-event data, and emphasizes the importance of using the drug under medical supervision.

Stigma Reduction and Awareness:

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

• Lilly is working to reduce stigma by reframing obesity as a disease, and its "We Now Know" campaign aims to promote early diagnosis and encourage people to seek medical guidance instead of delaying care.

Future Plans:

• Lilly is studying maintenance therapies, oral formulations, and next-generation medicines to support long-term patient needs.
• The company is focused on continuing to scale its reach across India, with a partnership with Cipla aiming to expand access beyond major urban centers.
• Pricing decisions will continue to reflect the value that Lilly believes the drug provides to individuals and society overall.